IA
IONS icon

IndexIQ Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

IndexIQ Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$61K Buy
+1,639
New +$53.6K ﹤0.01% 1125

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

IndexIQ Advisors's IONS Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Ionis Pharmaceuticals (IONS) in Q1 2022: 1,639 shares worth $61K. The stake represents ﹤0.01% of the portfolio and ranks #1125 among its holdings.

332 funds tracked by Wall St. Rank hold IONS as of Q1 2022.

  • IndexIQ Advisors held 1,639 shares of Ionis Pharmaceuticals worth $61K as of Q1 2022.
  • Ionis Pharmaceuticals was a new IndexIQ Advisors position in Q1 2022.
  • Ionis Pharmaceuticals made up ﹤0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #1125 holding.
  • 332 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.